Home / Combinations / CJC-1295 + Ipamorelin + BPC-157
CombinationMuscle GrowthRecoveryAnecdotal evidence
CJC-1295 + Ipamorelin + BPC-157
Recovery & GH
A popular performance and recovery stack combining the GH secretagogue synergy of CJC-1295 and Ipamorelin with BPC-157's direct tissue healing and anti-inflammatory effects. The GH component supports protein synthesis, body composition, and systemic recovery, while BPC-157 targets localised tissue repair, tendon and ligament healing, and gut integrity. This three-peptide combination is widely used by athletes seeking both systemic anabolic support and targeted injury recovery simultaneously.
Stack components
BPC-157Compound 01
CJC-1295 (without DAC)Compound 02
IpamorelinCompound 03
3
Compounds
3
Sources on file
244
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
BPC-157
The primary localised repair agent, targeting tendon, ligament, and muscle healing while also supporting gut integrity — the most common acute recovery bottleneck in high-load training contexts.
Compound 02
CJC-1295 (without DAC)
Provides the GHRH backbone for sustained GH secretion, supporting systemic protein synthesis, body composition, and broader recovery alongside BPC-157's targeted tissue repair.
Compound 03
Ipamorelin
Complements CJC-1295 with selective ghrelin-receptor stimulation to enhance GH pulse amplitude while avoiding the cortisol and prolactin elevation associated with less selective secretagogues.
Composition
3 compounds · 2 research areas
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
All three are unapproved research compounds. The CJC-1295 and Ipamorelin components are contraindicated in active or hormone-sensitive malignancies due to GH stimulation. BPC-157 has demonstrated pro-angiogenic properties in animal models, extending the malignancy caution to the full stack. No formal safety data exists for this triple combination; each compound's individual risk profile applies independently.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references3 sources
Moderate
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
J Clin Endocrinol Metab 2006
PeptideBase notePer-component source only — no combination study exists
Moderate
Ipamorelin, the first selective growth hormone secretagogue
Eur J Endocrinol 1998
PeptideBase notePer-component source only — no combination study exists
Moderate
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Curr Pharm Des 2011
PeptideBase notePer-component source only — no combination study exists
Related combinations3 share an area
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.